com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. 1-438. MONTREAL, Jan. Cookies are used to offer you a better browsing experience and to analyze our traffic. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced an update on the plan to amend and optimize the protocol of its Phase 1 oncology. 03) EPS for the quarter, beating the consensus estimate of ($0. Gain a better understanding of ETFs with our ETF Insights and ETF 101 resource. ET. Theratechnologies Inc. com uses cookies on this site. MONTREAL, June 29, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Read More. By continuing to use our service, you agree to our use of cookies. Theratechnologies had a negative net margin of 36. Stockhouse. Market Cap. Cookies are used to offer you a better browsing experience and to analyze our traffic. Further information about Theratechnologies is available on the Company's website at on SEDAR at and on EDGAR at MONTREAL, April 03, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. 06 million, an increase of. View real-time stock prices and stock quotes for a full financial overview. By continuing to use our service, you agree to our use of cookies. Type: Company - Public (TH) Revenue: $5 to $25 million (USD) Biotech & Pharmaceuticals. Real-time Price Updates for Theratechnologies (TH-T), along with buy or sell indicators, analysis, charts, historical performance, news and more(2018-03-06 | TSX:TH) Theratechnologies Announces FDA Approval of Breakthrough Therapy, Trogarzo™ (ibalizumab-uiyk) Injection, the First HIV-1 Inhibitor and Long-Acting Monoclonal Antibody for Multidrug Resistant HIV-1. Theratechnologies Appoints New Board Member. com. is a pharmaceutical company, which engages in addressing medical needs of patients with Human Immunodeficiency Virus (HIV). Stockhouse. TH1902 Study Published in Pharmaceutics Demonstrates Inhibition of Human Sortilin (Sort1)-Positive Ovarian and Triple-Negative Breast Cancer Stem-Like Cells and Tumor Growth Sep 13. SORT1 is a “scavenger” receptor that plays a significant role in protein internalization, sorting, and. com. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that the Company will present data from tissue microarrays showing high. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today reported business highlights and financial results for the third quarter of fiscal year 2022, ended August. 250 Howe Street, Suite 1400 Vancouver, British Columbia, V6C 3S7 Click to expand. (2013-04-03 | TSX:TH) Theratechnologies Inc. The firm offers its product under the brand name of. Cookies are used to offer you a better browsing experience and to analyze our traffic. According to 3 analysts, the average rating for THTX stock is "Buy. Theratechnologies inc. Last Reviewed: February 24, 2023. com uses cookies on this site. MONTREAL, Oct. TH1902 Study Published in Pharmaceutics Demonstrates Inhibition of Human Sortilin (Sort1)-Positive Ovarian and Triple-Negative Breast Cancer Stem-Like Cells and Tumor Growth Sep 13. com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. " The 12-month stock price forecast is $18. Share your ideas and get valuable. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that all five of the U. View recently published Stock News reports from independent reports and journalists. MONTREAL, July 23, 2021 /CNW Telbec/ - Theratechnologies Inc. a biopharmaceutical company focused on the development and commercialization of innovative therapies, today initiated enrollment of patients in the basket portion of the first-in-human study of TH1902, Theratechnologies’ investigational lead peptide drug conjugate (PDC) for the treatment of sortilin-expressing. Theratechnologies Inc. 0. TH 48% v4,15M c1. Heures de négociation. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. 5000 +0. Theratechnologies Unveils New Positive Data for Its Investigational Peptide-Drug Conjugates Targeting Sortilin Positive Cancers. FY2023 Revenue Guidance Range Confirmed Between $90 million and $95 million; Growth of the Commercial Portfolio in the Range of 13% and 19%. Cookies are used to offer you a better browsing experience and to analyze our traffic. MONTREAL, Oct. 31K. (TSX: TH) (NASDAQ: THTX) (“Theratechnologies”), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it will report financial results for its first quarter 2023 ended February 28, on Wednesday, April 12. Amendments Allow Theratechnologies to Maintain Minimum Liquidity of US$15 Million up to and until October 31, 2023. com. 51 S1. (TSX: EXRO) (OTCQB: EXROF) (the "Company" or "Exro" ), a leading clean technology company which has developed a new class of power electronics for electric motors and powertrains, announced today its financial results for the three months ended March 31, 2022. (Theratechnologies, or the Company (on a consolidated basis)) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on. The company's proprietary technologies include Long Acting Peptides, a peptide stabilization technology that. This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated December 16, 2021 to its short form base shelf prospectus dated December 14, 2021. [email protected] Reports Financial Results for the Third Quarter of Fiscal 2022 and Provides Business Update T. Further information about Theratechnologies is available on the Company's website at , on SEDAR at and on. Theratechnologies Inc. Further. 40 f102M H1. (2021-11-03 | TSX:TH) Theratechnologies to Present at the Credit Suisse 30th Annual Healthcare Conference on November 11, 2021. 51 to 200 Employees. Theratechnologies Inc. MONTREAL, Nov. Trogarzo ® is a long-acting, CD4-directed, post-attachment HIV-1 inhibitor. By continuing to use our service, you agree to our use of cookies. TORONTO, Sept. (2021-03-20 | TSX:TH) Theratechnologies Announces New Data Demonstrating Tesamorelin's Positive Effect on Immune Response Linked to Liver Inflammation. We currently market prescription products for people with HIV in the United States. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical. Cookies are used to offer you a better browsing experience and to. lgibson. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. 40%) (As of 11/17/2023 ET) Compare Today's Range $1. 74M. T. Watch list NEW Set a price target alert After Hours Last. Biopharmaceutical company Theratechnologies Inc. com uses cookies on this site. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. During the last trading day the stock fluctuated 12. Stockhouse. MONTREAL, July 12, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. com uses cookies on this site. (2021-05-31 | TSX:TH) Theratechnologies Hires Vice President, Human Resources. THTX | Complete Theratechnologies Inc. MONTREAL, Nov. 9 million as at August 31, 2023. Focused on small-cap companies and sectors. TO) stock quote, history, news and other vital information to help you with your stock trading and investing. Theratechnologies inc. (“Theratechnologies” or the “Company”) (Nasdaq: THTX; TSX: TH), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has closed its previously announced publi. (“Theratechnologies”) with the Securities and Exchange Commission (the. Real-time discussion about Theratechnologies Inc. com uses cookies on this site. Theratechnologies Inc. THERATECHNOLOGIES INC. . 15, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. stockhouse. 2 million. Stockhouse. Theratechnologies (TH) has announced preclinical findings for its peptide-drug conjugate TH1902 for the treatment of metastatic cancers. 00. Theratechnologies Announces 1-for-4 Reverse Stock Split. Shares of Theratechnologies are up 4. By continuing to use our service, you agree to our use of cookies. Stockhouse. stock news by MarketWatch. However, it did not meet the equivalence limits of 0. 9 million and US$19. The business had revenue of $27. com uses cookies on this site. MONTREAL, July 23, 2021 /CNW Telbec/ - Theratechnologies Inc. Cookies are used to offer you a better browsing experience and to analyze our traffic. Theratechnologies’ R&D staff is bearing the brunt of. A high-level overview of Theratechnologies Inc. B2Gold Declares Fourth Quarter 2023 Dividend. (“Theratechnologies” or the “Company”) (TSX: TH) today announced that it has applied to list its common shares on NASDAQ. FY2023 Revenue Guidance Range Confirmed Between $90 million and $95 million; Growth of the Commercial Portfolio in the Range of 13% and 19%. com uses cookies on this site. We also use them to share usage. e. : Renegotiated Lease to Generate Substantial Annual Savings. Theratechnologies Inc. Early Warning Report Issued Pursuant to National Instrument 62-103 - Acquisition of Securities of Theratechnologies Inc. We also use them to. (TH. Montréal, Québec, Canada . com uses cookies on this site. com uses cookies on this site. com uses cookies on this site. Montreal-based biopharmaceutical company Theratechnologies Inc. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. 23 to a day high of $1. , that crews have been mobilized to prepare for the 2022 exploration program at the Treaty Creek property, located in the heart of the. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. About Us | Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today presented preclinical data that demonstrate the potential utility of its lead investigational. Cookies are used to. Theratechnologies is leveraging its SORT1+ Technology™ to develop a new class of therapy that targets sortilin (SORT1)-positive cancers by linking anticancer drugs to proprietary peptides that specifically bind to the sortilin receptor. Theratechnologies is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies. com. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Christian Marsolais, Ph. MONTREAL, April 12, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. com uses cookies on this site. La Bourse de Toronto a perdu. 1 Wall Street analysts have set twelve-month price targets for Theratechnologies in the last year. Cookies are used to offer you a better browsing experience and to analyze our traffic. Amendments Allow Theratechnologies to Maintain Minimum Liquidity of US$15 Million up to and until October 31, 2023. 03, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. First Quarter Fiscal 2022 Financial Results. Headquartered in Montreal, Theratechnologies is a biotech company that develops innovative therapies for unmet medical needs in HIV, oncology, and NASH, a type of liver disease. Stockhouse. com. Theratechnologies is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies. Theratechnologies Reports Financial Results and Business Updates for the Fourth Quarter and Full Year Fiscal 2022. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovative therapies announced today that it will report its financial results for the second quarter of fiscal 2021 ended May 31, 2021 on Wednesday. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. MONTREAL, Aug. /NOT FOR DISTRIBUTION TO UNITED STATES OF AMERICA WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES OF AMERICA/. (2018-12-03 | TSX:TH) Theratechnologies Appoints New Chief Commercial Officer. 24, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Theratechnologies présente des données démontrant la surexpression de la sortiline (SORT1) dans plusieurs types de tumeurs au 34e symposium de l’EORTC-NCI-AACRVice President, Communications and Corporate Affairs. 5000 0. Trogarzo® and. Stockhouse. FAQ – Utilisateurs de TMX Argent NOUVEAU. RESSOURCES. Track Theratechnologies Inc. 5%. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that President and CEO, Paul Lévesque has issued an open letter to shareholders. 8. We changed the address of the Stockhouse website from to stockhouse. Stockhouse. View real-time stock prices and stock quotes for a full financial overview. Share your ideas and get valuable insights from the community of like minded traders and investors Headquarters. Theratechnologies Inc. Theratechnologies (TSX:TH)has indicated that Trogarzo did not meet its primary endpoints in its IM method study. MONTREAL, Aug. We also use them to share usage. MONTREAL, Dec. com. If you have JavaScript enabled then this page should refresh automatically, if it does not then please tap the button below. 3089 Background: SORT1 is expressed in a variety of tumors when compared to most healthy tissue. VANCOUVER, British Columbia, Nov. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Canada’s largest financial portal for Canadian small-cap investors is right here at Stockhouse where our Bullboards are a leading forum. 2015 Peel Street, 11th Floor Montréal, Québec Canada H3A 1T8 Phone: 514 336-7800 Fax: 514 331-9691Theratechnologies Announces Amendment to its Term Loan Facility With Affiliates of Marathon Asset Management. Message Board Total Posts: 4. Theratechnologies Inc. Stockhouse. MONTREAL, July 14, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. MONTREAL, Dec. T. M. (“Theratechnologies” or “the Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the strengthening of its global commercial. 26, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. One reason for that is that this tier does not include penny stocks. Amount of cash a business has after it has met its financial obligations such as debt and outstanding payments. com. com uses cookies on this site. Cookies are used to offer you a better browsing experience and to analyze our traffic. (2021-06-30 | TSX:TH) CORRECTION: Theratechnologies to Announce Financial Results for Its Second Quarter Fiscal 2021. Biopharmaceutical company Theratechnologies Inc. (NASDAQ:NASDAQ:THTX) Q1 2022 Earnings Conference Call April 13, 2022 8:30 AM ETCompany ParticipantsPaul Levesque - President & CEOPhilippe Dubuc - SVP &. Theratechnologies Inc. Stock analysis for Theratechnologies Inc (TH:Toronto) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Image source: The Motley Fool. 2015 Peel, 11th Floor Montreal, Quebec H3A 1T8 THERA technologies MANAGEMENT’S DISCUSSION AND ANALYSIS FOR THE YEAR ENDED NOVEMBER 30, 2021 The following Management’s Discussion and Analysis, or MD&A, provides Management’s point of view on the financial position and results of operations. H. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX) ), a biopharmaceutical company focused on the development. We currently market prescription products for people with HIV in the United States. -986. 08 (+6. View real-time stock prices and stock quotes for a full financial overview. 54% and a negative trailing twelve-month return on equity of. By continuing to use our service, you agree to our use of cookies. /NOT FOR DISTRIBUTION TO UNITED STATES OF AMERICA WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES OF AMERICA/. 18% on the last trading day (Wednesday, 25th Oct 2023), rising from $1. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced preliminary efficacy data from a Phase 1 study of its lead investigational peptide-drug. Stockhouse. (TSX: TH) announced today that the Supreme Court of Canada has granted its appeal and dismissed 121851 Canada Inc. com uses cookies on this site. We also use them to share usage. Browse posts by Sector and Subsector. Cookies are used to offer you a better browsing experience and to analyze our traffic. Their average twelve-month price target is $36. We also use them to share usage information with our partners. By continuing to use our service, you agree to our use of cookies. - 2023 Q3 positive adjusted EBITDA to be achieved. Theratechnologies affirms fiscal 2022 revenue to be in the range of $79 million and $84 million for full fiscal 2022, or growth of the commercial portfolio to be in the range of 13% and 20% as compared to the 2021 fiscal year. . Theratechnologies has generated ($1. Theratechnologies layoffs. (THTX) NasdaqCM - NasdaqCM Real Time Price. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. (THTX) Stock Price, Quote, latest community messages, chart, news and other stock related information. We also use them to share usage. Stockhouse. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Stockhouse. 9%, while the Biotechs industry saw earnings growing at 17. m. com uses cookies on this site. Investor Relations. See the latest Theratechnologies Inc stock price (THTX:XNAS), related news, valuation, dividends and more to help you make your investing decisions. Theratechnologies Announces Certain Preliminary Q3 2023 Financial Highlights. The website address for Stockhouse has changed We changed the address of the Stockhouse website from to stockhouse. (TSX: TH, Forum) has long been a favourite among Healthcare Bullboard posters who have been following its developments to commercialize innovative therapies. (TSX: TH, Forum) noted that its Q1 2022 consolidated sales grew 20%, supported by 35% growth in sales of EGRIFTA SV formulation. By continuing to use our service, you agree to our use of cookies. 04, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Theratechnologies’ CFO to Attend Cantor Global Healthcare Conference in New York City. com uses cookies on this site. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today presented data suggesting that tesamorelin may improve metabolic profiles in people with HIV. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. By continuing to use our service, you agree to our use of cookies. 46. Theratechnologies Inc. 11/05/2020 4:15:02 PM. Theratechnologies, Inc. Theratechnologies Reports Financial Results for the Third Quarter of Fiscal 2022 and Provides Business Update. (THTX) Stock Price, Quote, latest community messages, chart, news and other stock related information. 89 $2. . MONTREAL, April 12, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Track Theratechnologies Inc. 2015 Peel Street, 11th Floor Montréal, Québec Canada H3A 1T8 Phone: 514 336-7800 Fax: 514 331-9691. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has decided to pause the enrollment of patients in its Phase 1 clinical trial of. Theratechnologies was founded in 1993 and is headquartered in Montreal, Canada. MONTREAL, July 31, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. When this page refreshes you will be logged in with the new address. By continuing to use our service, you agree to our use of cookies. Top 173 largest Canadian Companies in the Drug Manufacturers—Specialty & Generic industry by Market Cap. About Theratechnologies Theratechnologies (TSX:TH) is a specialty pharmaceutical company addressing unmet medical needs to promote healthy ageing and an improved quality of life among HIV patients. Lead drug EGRIFTA (tesamorelin for injection) is being marketed for the reduction of excess abdominal fat in HIV-infected patients with. TH1902 is currently Theratechnologies’ lead investigational peptide drug conjugate candidate for the treatment of cancer derived from its SORT1+ Technology™. The Notes were issued under a trust indenture dated as of June 19, 2018, by and among Theratechnologies and Computershare Trust Company of Canada. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the Company will report financial results and provide a business update for its third. ("Theratechnologies" or the "Company"). Theratechnologies . The business had revenue of $27. com uses cookies on this site. C. We also use them to share usage information with our partners. MONTREAL, Feb. 1-514-336-7800. - On track to meet FY2022. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Stockhouse. View real-time stock prices and stock quotes for a full financial overview. Apr 14, 2020, 8:30 a. 12, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. com 10/16/2023. MONTREAL, June 30, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced it will report financial results and provide a business update for its second. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. By continuing to use our service, you agree to our use of cookies. T. Theratechnologies will acquire all outstanding shares of Katana for US$5,300,000 or CA$6,900,000. Further. (THTX) Stock Price, Quote & News - Stock Analysis -20. 14, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Theratechnologies Announces First Patient Dosed in Phase 1 Clinical Trial of TH1902 for Sortilin Positive Solid Tumors. By continuing to use our service, you agree to our use of cookies. 01, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or “the Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the Company’s participation in three poster presentations at the 2022 Annual Meeting. About Theratechnologies Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical. com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. TH1902 is currently Theratechnologies’ lead investigational PDC candidate for the treatment of cancer derived from its SORT1+ Technology™. FY2022 revenue. 65 per cent to C$1. The price has fallen in 5 of the last 10 days. Theratechnologies is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies. Philippe Dubuc Senior Vice President and Chief Financial Officer Phone: +1-438-315-6608 [email protected] uses cookies on this site. com. MONTREAL, June 29, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Theratechnologies affirms fiscal 2022 revenue to be in the range of $79 million and $84 million for full fiscal 2022, or growth of the commercial portfolio to be in the range of 13% and 20% as. com uses cookies on this site. Presented in part at the XVI International AIDS Conference; August 13–18, 2006; Toronto, Canada (abstracts TUP30058 AND THLB0218). US Headquarters. NCU. Stockhouse. com uses cookies on this site. Rosenberg, Reference is made to your letter dated August 16, 2012 regarding the Form 40-F for fiscal year-end November 30, 2011 filed by Theratechnologies Inc. (THTX) stock quote, history, news and other vital information to help you with your stock trading and investing. Investor inquiries: Elif McDonald. Cookies are used to offer you a better browsing experience and to analyze our. Cookies are used to offer you a better browsing experience and to analyze our traffic. . 26, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Theratechnologies Inc. For investor inquiries: Leah Gibson. (2020-10-16 | TSX:TH) Theratechnologies Appoints Two New Board Members. Cookies are used to offer you a better browsing experience and to analyze our traffic. There are 102 news items for this page. Biopharma Theratechnologies (NASDAQ:THTX) Friday announced that a study evaluating an intramuscular (IM) method of administration for its therapy, Trogarzo, did not meet the primary endpoint. com uses cookies on this site. Theratechnologies Stock Price, News and Company Updates. S. 36 morning pop. Theratechnologies develops and commercializes innovative therapies. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies,. com uses cookies on this site. 39 50-Day Range $0. ( THTX 3. MONTREAL, Jan. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. . MONTREAL, July 07, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (TH. (“Theratechnologies” or the “Company”) (Nasdaq: THTX; TSX: TH), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has closed its previously announced publi. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, reported the voting results from its annual meeting of shareholders held today in a virtual-only setting. TO) Stock Price, News, Quote & History - Yahoo Finance Canada Markets close in 43 mins S&P/TSX 20,125. MONTREAL, March 29, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. TH1902, the leading product candidate derived from the SORT1+ Technology, is a first-in-class peptide-drug. P. High expression of the sortilin (SORT1) receptor correlates with decreased survival in triple‐negative breast cancer (TNBC) patients. Early Warning Report Issued Pursuant to National Instrument 62-103 - Acquisition of Securities of Theratechnologies Inc. ) Clinical-stage pharmaceutical company Theralase Technologies Inc. T. Theratechnologies Europe Limited 1st Floor, 12 Duke Lane Upper Royal Hibernian Way DUBLIN Dublin 2 Ireland D02 DX07 Phone: +353 1 215 0650 [email protected] is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies. (882) posted 3 minutes ago.